Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.

PURPOSE The purpose of this study was to establish a sensitive and semiquantitative method for the detection of minimal residual disease of neuroblastoma, the most common solid tumor in childhood. EXPERIMENTAL DESIGN Analysis was performed on a molecular level by reverse transcription-PCR using a new, real-time detection method. We measured two genes simultaneously, tyrosine hydroxylase (TH) as the target gene and glyceraldehyde-3-phosphate dehydrogenase as a reference gene, in blood and bone marrow samples at diagnosis and after follow-up from six patients with neuroblastoma, one patient with ganglioneuroma, and one patient with ganglioneuroblastoma. RESULTS The sensitivity of the assay was 1:10(6) peripheral WBCs. Four patients with stage IV neuroblastoma and one patient with stage III neuroblastoma were scored positive. The other stage III patient and the other two patients with ganglioneuroma and ganglioneuroblastoma followed by acute lymphoblastic leukemia, respectively, were scored negative. Control bone marrow aspirates were also negative. The TH assay is more sensitive than immunohistochemical detection, and the results of the TH assay corresponded with the results of MYCN amplification. CONCLUSIONS The described TH assay is specific, sensitive, and semiquantitative and can be used for the detection of neuroblastoma cell involvement in bone marrow and blood at diagnosis and during therapy. Furthermore, the TH assay is a possible prognostic marker for neuroblastoma.

[1]  Thomas D. Schmittgen,et al.  Real-Time Quantitative PCR , 2002 .

[2]  N. Cheung,et al.  Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  R. Seeger,et al.  Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma. , 2001, Journal of pediatric hematology/oncology.

[4]  K. Horibe,et al.  Disease Outcome May Be Predicted by Molecular Detection of Minimal Residual Disease in Bone Marrow in Advanced Neuroblastoma: A Pilot Study , 2001, Journal of pediatric hematology/oncology.

[5]  生野 久美子 Clinical Implications of Minimal Disease in the Bone Marrow and Peripheral Blood in Neuroblastoma , 2001 .

[6]  K. Matsumoto,et al.  Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. , 2001, Medical and pediatric oncology.

[7]  C. R. Pinkerton,et al.  Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. , 2001, Medical and pediatric oncology.

[8]  W. London,et al.  MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Y. Fujii,et al.  Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma. , 2000, Journal of pediatric surgery.

[10]  A. Tischler Divergent differentiation in neuroendocrine tumors of the adrenal gland. , 2000, Seminars in diagnostic pathology.

[11]  S. Burchill,et al.  Molecular detection of low‐level disease in patients with cancer , 2000, The Journal of pathology.

[12]  G. Tonini,et al.  Real-time quantitative PCR for the measurement of MYCN amplification in human neuroblastoma with the TaqMan detection system. , 1999, Clinical chemistry.

[13]  M. Haber,et al.  Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies. , 1999, The American journal of pathology.

[14]  S. Burchill,et al.  Reverse Transcriptase Polymerase Chain Reaction Cell Lines and Preparation of Cell Spikes Improved Methods Using the Reverse Transcriptase Polymerase Chain Reaction to Detect Tumour Cells , 2022 .

[15]  B. Bernardi,et al.  High-sensitivity immunocytologic analysis of neuroblastoma cells in paired blood and marrow samples. , 1998, Journal of hematotherapy.

[16]  E. Yunis,et al.  Detection of Neuroblastoma in the Bone Marrow: Biopsy Versus Aspiration , 1998, Journal of pediatric hematology/oncology.

[17]  J. Stéphan,et al.  Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. , 1998, Medical and pediatric oncology.

[18]  G. Seitz,et al.  Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. , 1997, European journal of cancer.

[19]  K. Sano,et al.  Detection of low numbers of neuroblastoma cells in vitro. , 1997, Annals of the Academy of Medicine, Singapore.

[20]  S. Mizutani,et al.  Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction. , 1997, Journal of pediatric surgery.

[21]  C. Heid,et al.  A novel method for real time quantitative RT-PCR. , 1996, Genome research.

[22]  U. Keilholz Diagnostic PCR in melanoma, methods and quality assurance. Epalinges, Switzerland, 26/27 January 1996 , 1996 .

[23]  K. Horibe,et al.  Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription‐polymerase chain reaction for tyrosine hydroxylase mRNA , 1996, Cancer.

[24]  S. Burchill,et al.  Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. , 1995, European journal of cancer.

[25]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[26]  A. Evans,et al.  Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: an update. , 1994, Medical and pediatric oncology.

[27]  T. Klingebiel,et al.  Peripheral stem cell transplantation in neuroblastoma stage 4 with the use of [131I-m]IBG. , 1994, Progress in clinical and biological research.

[28]  R. Abramson,et al.  Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Seeger,et al.  Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. , 1991, Pediatric clinics of North America.

[30]  H. Sather,et al.  Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. , 1991, The New England journal of medicine.

[31]  B. Bostrom,et al.  Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. , 1990, Blood.

[32]  J. Zucker,et al.  High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Adolph E. Christ,et al.  Childhood cancer , 2020, The Downstate Series of Research in Psychiatry and Psychology.